PSS21 Cost-effectiveness of Aflibercept in the treatment of wet age-related Macular Degeneration in Turkey  by Tunalioglu, A. et al.
A182  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
OBJECTIVES: The objective of this study is to evaluate the cost-effectiveness of 
aflibercept compared to ranibizumab for the treatment of wet age-related macular 
degeneration (wAMD) in Turkey. METHODS: A Markov model consisting of six health 
states on vision impairment as “no vision impairment; mild vision impairment; 
moderate vision impairment; severe vision impairment; total blindness; death” 
with a 20-year timeframe was adapted to the Turkish setting through an expert 
panel. Clinical transition inputs between visual acuity states and safety data were 
mainly derived from the results of Phase III VIEW-1 and VIEW-2 trials. Economic 
inputs were based on the expert opinion addressing local treatment, monitoring and 
adverse event management algorithms. The primary and secondary endpoints for 
the study were blind years and QALYs, respectively. Analyses were conducted from 
the Turkish Payer Social Security Institution perspective. All costs were calculated in 
Turkish Liras (TL) and then converted to USD using TL/USD currency rate as 2,1 (mid-
2014). RESULTS: Aflibercept was associated with 6,614 blind years and 4,805 QALYs, 
while ranibizumab was associated with 6,599 blind years and 4,810 QALYs; resulting 
in total of 0,015 more blind years and 0,005 less QALYs for aflibercept compared 
with ranibizumab in the treatment of wAMD. Total costs associated with aflibercept 
and ranibizumab were 25.954 USD and 30.311 USD respectively; resulting with a 
total of 4.357 USD less costs for aflibercept compared with ranibizumab, driven 
by savings in medication, administration and monitoring costs. CONCLUSIONS: 
Aflibercept was found as the cost-effective treatment option when compared with 
ranibizumab in the treatment of wAMD in Turkish setting. Aflibercept was associ-
ated with significant less cost leading to savings in medication, administration and 
monitoring costs; while being clinically equivalent with negligible benefits as blind 
years averted and QALYs gained in comparison with ranibizumab.
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OBJECTIVES: Routine clinical practice in UK patients with severe dry eye disease 
is a combination of artificial tears (AT) and ocular lubricant ointments. This study 
aims to assess the cost-effectiveness to the UK NHS of the addition of Ikervis® 
(Ciclosporin A; CsA) to routine practice for patients who have not adequately 
responded to therapy. METHODS: Using a Markov framework, future health effects 
and costs were modeled. Eligible patients receive six months therapy with Ikervis® 
plus AT and ocular lubricants or AT and ocular lubricants without CsA. Upon com-
pletion, those who respond sufficiently remain on CsA treatment for the dura-
tion of the response, achieving a higher quality of life (HRQoL) and lower AT use. 
Incremental cost effectiveness ratios (ICER) were expressed in GBP (£) per QALY 
gained with costs and health effects discounted at 3.5% over a lifetime time hori-
zon. Deterministic and probabilistic sensitivity analyses were employed to assess 
the effect of uncertainty on the model. Scenario analyses including less stringent 
improvement criteria, alternative approaches to deriving response stratified utility 
values and a shorter initial trial period were performed. RESULTS: Compared with 
AT alone, Ikervis® results in a lifetime cost to the UK NHS of £713 per patient, but 
offers an additional 0.04 QALYs. The ICER is £19,156/QALY gained. At a commonly 
accepted cost-effectiveness threshold of £30,000 per QALY, Ikervis® is cost-effective 
in 70.8% of simulations. Tornado analysis showed the model is most sensitive to 
the incremental benefit on patient’s long-term HRQoL associated with respond-
ing to therapy compared with non-response. CONCLUSIONS: The modelling study 
showed that from an NHS perspective, health gains can be achieved at a low cost. 
The Ikervis® ICERs are well below the NICE’s commonly accepted cost-effectiveness 
threshold of £30,000/QALY gained, indicating that Ikervis® in the target patient 
population would represent a cost-effective intervention in the UK.
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OBJECTIVES: To check prescribing pattern for glaucoma and to design a treatment 
guideline for POAG that is more cost effective from the perspective of a third party 
payer than the current practice based on real world evidence METHODS: A retrospec-
tive descriptive study of glaucoma patients was carried out with the aid of data col-
lection form. The prices (95% CL) of antiglaucoma drugs were estimated from hospital 
price list and the 5 nearby community pharmacies. Eighty randomly selected case 
notes of glaucoma patients on therapy for at least 3 months were studied. Data col-
lected were the demographics and diagnosis, IOP per month and the drugs prescribed. 
A Stochastic Monte model based on the outcome and cost was constructed with the 
aid of vanguard studio 5.0 (Cary, North Carolina, USA). The outcome of the therapy 
which was entered as the proportion of patients whose IOPs were normal, reduced 
or either increased or unchanged per month of treatment. Sensitivity analysis was 
conducted by varying the input data by ±50%. RESULTS: The proportion of patients 
that IOP was checked regularly was low 26.76% .The commonly prescribed drugs 
were the beta blockers and carbonic anhydrase inhibitors. The current practice will 
cost USD430.86 (NGN 77,783.76) per patient per annum whereas the proposed guide-
line that result in improved outcome will cost USD 44.10 (NGN7, 953.12). Treatment 
guideline is absent in Standard treatment guideline of Nigeria CONCLUSIONS: The 
patients that IOP was checked regularly were low and multi therapy was prescribed 
at onset with the Beta blockers plus Carbonic anhydrase inhibitors. A cost savings of 
NGN69, 830.64 will be obtained by the proposed guideline for POAG per patient per 
annum thus it could be adopted after evaluation at several sites
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relative to ranibizumab and dexamethasone. Total costs associated with afliber-
cept, ranibizumab and dexamethasone were 4.260 USD, 5.219 USD and 1.631 USD 
respectively, resulting for the cost of aflibercept treatment being 959 USD lower 
compared to ranibizumab and 2.629 USD higher compared to dexamethasone. 
Aflibercept was dominant over ranibizumab. The ICER for aflibercept as compared 
to dexamethasone was calculated as 7.144 USD/QALY. CONCLUSIONS: For the 
treatment of CRVO in Turkish setting, aflibercept was found to be the dominant 
treatment option when compared with ranibizumab while being more effective 
and less costly. Compared with dexamethasone aflibercept was found as cost-
effective with an ICER of 7.144 USD, well below the willingness-to-pay threshold 
(GDP per capita „Ÿ 10.782 USD) for Turkey.
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OBJECTIVES: To assess the cost-effectiveness of secukinumab versus current 
therapies for plaque psoriasis in adults from the Canadian healthcare perspec-
tive. METHODS: A Markov model was designed to determine the cost-effectiveness 
of secukinumab 300mg for moderate to severe plaque psoriasis over a 10-year hori-
zon versus secukinumab 150mg, adalimumab, etanercept, infliximab, ustekinumab 
(45mg or 90mg), and standard of care (oral systemics, topicals, and phototherapy, 
SoC). Year 1 of the model consisted of 4-week cycles with 4 Psoriasis Area and 
Severity Index (PASI) response level-based health-states (PASI ≥ 90, 75-89, 50-74, 
and < 50). Years 2-10 used annual cycles, with 3 health-states (PASI ≥ 75, PASI <75, 
and death).  Decisions to switch to SoC were made at week 12 and 52, then annually. 
Efficacy data from a network meta-analysis informed first-year model transitions. 
Resource use, costs, and utilities were collected from clinical trials, published lit-
erature, expert opinion, and standard Canadian sources. RESULTS: The order of 
treatments by increasing quality-adjusted life years (QALYs) were: SoC, etanercept, 
adalimumab, ustekinumab 45mg, secukinumab 150mg, ustekinumab 90mg, secuki-
numab 300mg, and infliximab. The cost-effectiveness frontier showed etanercept 
was strongly dominated, while adalimumab, ustekinumab 45mg, secukinumab 
150mg and ustekinumab 90mg were weakly dominated by secukinumab 300mg. 
The ICER for secukinumab 300mg versus SoC was $87,368/QALY gained. The ICER for 
infliximab versus secukinumab 300mg was $1,039,403/QALY gained. Deterministic 
sensitivity analyses indicated the results are most sensitive to time horizon, cost 
of biologics, and utility values. The probabilistic sensitivity analysis demonstrated 
that at a willingness-to-pay threshold of ~$90,000/QALY, secukinumab 300mg has 
the highest probability of being the cost-effective option. CONCLUSIONS: For adults 
with moderate to severe plaque psoriasis, secukinumab 300mg was associated with 
increased QALYs at a lower incremental cost compared to etanercept, adalimumab, 
ustekinumab and secukinumab 150mg. For each QALY gained versus SoC, treatment 
with secukinumab costed an additional $87,368.
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OBJECTIVES: To report the cost per outcome of a robust model to deliver glaucoma 
examinations to older Philadelphians at community centers. METHODS: The cost-
outcome analysis was performed taking a health system perspective, with outcome 
defined as diagnostic yield (cases of glaucoma detected and cases of any ocular dis-
ease detected). Costs included supplies (slit lamp, visual field machine, handheld 
fundus camera, laptops, medical and office supplies), travel (van rental, fuel, main-
tenance, personnel mileage reimbursements), and personnel time (for examination, 
travel to sites, training, and supervision). Personnel time was captured by time and 
motion data collected during site visits. Costs of community health workers and 
medical assistants were based on regional 2013 US Bureau of Labor and Statistics (BLS) 
wage rates, and ophthalmologist wages were based on 2013 NIH salary cap. Wage rates 
for project supervisors were assumed to be 25% more than a medical assistant. Fringe 
benefits were added to all wage costs at 31% (BLS). RESULTS: 1649 participants were 
examined from 2012-2013, of whom 68% were females, 70% were African-Americans, 
and the mean age was 69 (SD 11). The mean total examination time was 56 minutes 
(SD 4). Visual field and physician consult were the most time-consuming steps (11-13 
minutes each). Glaucoma and angle closure represented 17% of the 2197 diagnoses 
made. Other diagnoses made included glaucoma suspect (16%), cataracts (52%), dia-
betic retinopathy (2%), and macular degeneration (1%). Examination and staff travel 
were the largest components of total costs at $67,018 and $24,340, respectively. The 
total program cost was $229,082 ($139/participant). The cost/case of glaucoma diag-
nosis (confirmed, suspected or angle-closure) was $550. The cost/case to detect any 
ocular disease was $104. CONCLUSIONS: The cost to deliver glaucoma examinations 
through this program is relatively low in relation to its diagnostic yield, however 
opportunities exist to improve efficiency of examination and travel.
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